ATRIAL FIBRILLATION — GENETIC RISK

Atrial Fibrillation Genetic Risk — AFib has approximately 60% heritability, and in young patients with lone AFib, genetic evaluation identifies underlying ion channelopathies and cardiomyopathies that change the entire management approach.

Whole genome sequencing evaluates all AFib-associated genes — KCNQ1, KCNE2, SCN5A, NPPA, PITX2 regulatory variants, and cardiomyopathy genes (TTN, LMNA, MYH7) — distinguishing genetic AFib from typical age-related AFib.

KCNQ1
KCNE2
SCN5A
NPPA
PITX2
TTN
LMNA

About this condition

Atrial Fibrillation — Genetic Risk

Atrial fibrillation (AFib) is the most common sustained cardiac arrhythmia, affecting approximately 6 million Americans. While most AFib occurs in older adults with hypertension, valvular disease, or heart failure, approximately 10-15% presents as 'lone AFib' in younger patients (<60 years) without structural heart disease. AFib heritability is approximately 60% — among the highest of any common cardiovascular condition. Monogenic AFib is caused by gain-of-function variants in potassium channel genes (KCNQ1, KCNE2, KCNJ2 — shortening atrial action potential duration), loss-of-function sodium channel variants (SCN5A), and atrial natriuretic peptide variants (NPPA).

The clinical importance of genetic AFib evaluation extends beyond the arrhythmia itself. TTN truncation variants — the most common genetic cause of dilated cardiomyopathy — also significantly increase AFib risk, often with AFib preceding ventricular dysfunction by years. A young patient presenting with 'lone AFib' who carries a TTNtv may be in the early stages of DCM. LMNA variants similarly cause AFib often before the cardiomyopathy becomes clinically apparent. Identifying these cardiomyopathy genes transforms AFib management from 'rhythm and rate control' to 'cardiac surveillance and ICD evaluation for an underlying genetic cardiac disease.'

Common AFib susceptibility variants identified through GWAS — particularly at the PITX2 and ZFHX3 loci — contribute to polygenic AFib risk. Polygenic risk scores combining these variants can identify individuals at 2-5x elevated AFib risk, potentially informing screening intensity and anticoagulation thresholds. Additionally, pharmacogenomic variants affecting antiarrhythmic drug metabolism (CYP2D6 for flecainide, CYP2C9/VKORC1 for warfarin — both relevant to AFib management) are simultaneously captured by WGS.

Lone AFib in young patients may be the first sign of TTN or LMNA cardiomyopathy — the AFib can precede ventricular dysfunction by years. Genetic testing in young AFib patients identifies underlying cardiomyopathy before heart failure develops.

Gene locus: KCNQ1 (11p15.5-p15.4), KCNE2 (21q22.11), SCN5A (3p22.2), NPPA (1p36.22), PITX2 (4q25), TTN (2q31.2), LMNA (1q22)

Young-onset AFib is frequently the first manifestation of an underlying genetic cardiac condition. WGS evaluates ion channel, cardiomyopathy, and pharmacogenomic genes simultaneously — turning AFib diagnosis into comprehensive cardiac genetic evaluation.

TTN truncation variants cause AFib years before cardiomyopathy develops — genetic testing enables early cardiac surveillance

A young patient presenting with lone AFib who carries a TTNtv is not simply an AFib patient — they are a DCM patient whose cardiomyopathy has not yet manifested. Early identification enables serial echocardiographic surveillance, neurohormonal therapy initiation at the first sign of ventricular dysfunction, and family cascade screening. Without genetic testing, the cardiomyopathy diagnosis is delayed until clinical heart failure presents — missing the optimal window for early intervention.

Pharmacogenomic variants guide AFib drug selection — flecainide (CYP2D6) and warfarin (CYP2C9/VKORC1) metabolism varies by genotype

Flecainide, a first-line antiarrhythmic for paroxysmal AFib, is metabolized by CYP2D6. Poor metabolizers (~5-10% of Europeans) have dramatically higher flecainide levels, increasing the risk of proarrhythmia. Warfarin sensitivity depends on CYP2C9 and VKORC1 genotypes — pharmacogenomic dosing algorithms reduce bleeding risk. WGS provides both the structural cardiac genetic evaluation and the pharmacogenomic profiles for AFib drug management in a single comprehensive test.

Atrial Fibrillation Genetic Risk — AFib has approximately 60% heritability, and in young patients with lone AFib, genetic evaluation identifies underlying ion channelopathies and cardiomyopathies that change the entire management approach.

Atrial Fibrillation — Genetic Risk

Young-onset AFib is frequently the first manifestation of an underlying genetic cardiac condition. WGS evaluates ion channel, cardiomyopathy, and pharmacogenomic genes simultaneously — turning AFib diagnosis into comprehensive cardiac genetic evaluation.

TTN truncation variants cause AFib years before cardiomyopathy develops — genetic testing enables early cardiac surveillance

Pharmacogenomic variants guide AFib drug selection — flecainide (CYP2D6) and warfarin (CYP2C9/VKORC1) metabolism varies by genotype

Others in Cardiovascular

One test. A lifetime of answers.